Inherited Metabolic Diseases of the Nervous System, Hepatolenticular Degeneration (Wilson Disease)
Adams & Victors Principles of Neurology, Chp 37, pg 982, Ropper, A.H.,et al, 2014
Wilson Disease: Description of 282 Patients Evaluated Over 3 Decades
Medicine 86:112-121, Taly,A.B., et al, 2007
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Worsening of Neurologic Syndrome in Patients with Wilson's Disease with Initial Penicillamine Therapy
Arch Neurol 44:490-493, Brewer,G.J.,et al, 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Development of Neurologic Symptoms in a Patient with Asymptomatic Wilson's Disease Treated with Penicillamine
Arch Neurol 51:304-305, Brewer,G.J.,et al, 1994
Initial and Follow-up Brain MRI Findings and Correlation with the Clinical Course in Wilson's Disease
Neurol 44:1064-1068, Roh,J.K.,et al, 1994
Treatment with D-penicillamine Improves Dopamine D2-Receptor Binding and T2-Signal Intensity in de novo Wilson's Disease
Neurol 44:1079-1082, Schwarz,J.,et al, 1994
Wilson Disease
Medicine 71:139-164, Brewer,G.J.&Yuzbasiyan-Gurkan,V., 1992
Wilson Disease:Clinical Presentation, Treatment, and Survival
Ann Int Med 115:720-726, Stremmel,W.,et al, 1991
Wilson's Disease
In Oxford Textbook of Clin Hepatology, Oxford Univ Press, Vol 2, Ch 20. 1, p. 947, Sternlieb,I.&Scheinberg,I.H., 1991
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Cranial MRI in Wilson's Disease
Neuroradiology 32:211-214, Prayer,L.,et al, 1990
Wilson's Disease, Development of Neurological Disease after Beginning Penicillamine Therapy
Arch Neurol 47:595-596, Glass,J.D.,et al, 1990
Evoked Potentials in Assessment and Follow-up of Patients with Wilson's Disease
Lancet 336:963-964, Grimm,G.,et al, 1990
Diagnosis and Treatment of Presymptomatic Wilson's Disease
Lancet 2:435-437, Walshe,J.M., 1988
The Use of Trientine in Preventing the Effects of Interrupting Penicillamine Therapy in Wilson's Disease
NEJM 317:209-213, Scheinberg,I.H.,et al, 1987
The Pathophysiology of Penicillamine-Induced Myasthenia Gravis
Ann Neurol 20:740-744, Kuncl,R.W.,et al, 1986
Penicillamine-Induced Myositis
Am J Med 77:719-722, Halla,J.T.,et al, 1984
Treatment of Wilson's Disease
Ann Int Med 99:398-400, Cummings,J.N.,et al, 1983
Penicillamine-Induced Neuropathy in Rheumatoid Arthritis
Ann Int Med 95:457-458, Pool,K.D.,et al, 1981
Penicillamine-associated Myasthenia Gravis
Neurol 30:1246-1250, Albers,J.W.,et al, 1980
Myasthenia Gravis & Penicillamine Therapy of Rheumatoid Arthritis
JAMA 244:1822-1823, Bocanegra,T.,et al, 1980
Successful Treatment of Inorganic Mercury Neurotoxicity with N-acetyl-penicillamine Despite an Adverse Reaction
Neurol 30:1000-1001, Markowitz,L.,et al, 1980
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Diagnosis of Treatable Wilson's Disease
NEJM 298:1347, Cartwright,G.E., 1978
Penicillamine-induced Myasthenia Gravis Associated with Antibodies to Acetylcholine Receptor
Neurol 28:847-849, Russell,A.S.,et al, 1978
Cholelithiasis and Wilson Disease
J Pediatr 2:210-213, Rosenfield,N.,et al, 1978
Penicillamine-associated Myasthenia Gravis, Antiacetylcholine Receptor & Antistriational Antibodies
Am J Med 63:689, Masters,C.L.,et al, 1977
Mercury Poisoning in a Dentist
Arch Neurol 33:788, Iyer,K.,et al, 1976
Pregnancy in Penicillamine Treated PNts with Wilson's Disease
NEJM 293:1300, Scheinberg,I.H.,et al, 1975
Reversible Forms of Motor Neuron-Disease:Lead"Neuropathy"
Neurol 22:446, Boothby,J., 1972
Mercury Poisoning & its Treatment with N-Acetyl-D, L-Penicillamine
NEJM 285:10, Kark,R.A.,et al, 1971